Skip to Content
Merck
CN

SML0414

NCX 4040

≥98% (HPLC)

Synonym(s):

2-(Acetyloxy)benzoic acid 4-(nitroxymethyl)phenyl ester, NO-aspirin

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C16H13NO7
CAS Number:
287118-97-2
Molecular Weight:
331.28
NACRES:
NA.77
PubChem Substance ID:
329825409
UNSPSC Code:
12352200
MDL number:
MFCD08062164

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C16H13NO7/c1-11(18)23-15-5-3-2-4-14(15)16(19)24-13-8-6-12(7-9-13)10-22-17(20)21/h2-9H,10H2,1H3

SMILES string

CC(=O)Oc1ccccc1C(=O)Oc2ccc(CO[N+]([O-])=O)cc2

InChI key

CTHNKWFUDCMLIQ-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

storage condition

protect from light

color

white to beige

solubility

DMSO: 15 mg/mL (clear solution)

storage temp.

−20°C

Quality Level

100

Related Categories

Biochem/physiol Actions

NCX 4040 is a nitric oxide-donating form of aspirin.
NCX 4040 is a nitric oxide-donating form of aspirin. NCX 4040 inhibits cyclooxygenase activity and releases NO, which can down-regulate COX2 expression and reduce the levels of superoxide accumulation. In the human monocytic cell line THP1, the compound inhibits PGE2 production and cytokine expression, and appears to stabilize IkB by inhibiting proteasome function. NCX 4040 has been shown to induce apoptosis in several tumor cell lines.

Features and Benefits

This compound is featured on the Nitric Oxide Synthases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

signalword

Danger

Hazard Classifications

Aquatic Acute 1 - Eye Dam. 1 - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000078767
126M4761V
075M4735V
072M4716V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Anna Tesei et al.
Journal of translational medicine, 5, 52-52 (2007-11-01)
Despite numerous studies aimed at verifying the antitumor activity of nitric oxide-releasing nonsteroidal antiflammatory drugs (NO-NSAIDs), little is known about the molecular targets responsible for their antineoplastic properties. In the present study, we investigated the mechanisms underlying the cytotoxicity of
Paul Guedeney et al.
Journal of clinical medicine, 9(3) (2020-03-07)
The respective ischemic and bleeding risks of early aspirin discontinuation following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) remain uncertain. We performed a prospero-registered review of randomized controlled trials (RCTs) comparing a P2Y12 inhibitor-based single antiplatelet strategy
Anna Tesei et al.
Journal of translational medicine, 3(1), 7-7 (2005-02-05)
BACKGROUND: Nitric oxide-releasing nonsteroidal antiinflammatory drugs (NO-NSAIDs) are reported to be safer than NSAIDs because of their lower gastric toxicity. We compared the effect of a novel NO-releasing derivate, NCX 4040, with that of aspirin and its denitrated analog, NCX
Jung Min Song et al.
Carcinogenesis, 39(7), 911-920 (2018-07-10)
Although regular aspirin use has been shown to lower the risk of colorectal cancer, its efficacy against lung cancer is weak or inconsistent. Moreover, aspirin use increases the risk of ulcers and stomach bleeding. In this study, we determined the
Stefania Tacconelli et al.
Clinical pharmacology and therapeutics, 104(1), 111-119 (2018-03-27)
We studied the influence of cardiovascular (CV) risk factors, previous CV events, and cotreatments with preventive medicines, on residual platelet thromboxane (TX)B2 production in 182 patients chronically treated with enteric coated (EC)-aspirin (100 mg/day). The response to aspirin was also verified
View All Related Papers

Articles

Nitric Oxide Synthases

We offer many products related to nitric oxide synthases for your research needs.

一氧化氮合酶

我们针对客户的研究需求，提供了许多一氧化氮合酶相关的产品。

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service